Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Loading...
Loading...
  • Health Canada has approved Moderna Inc's MRNA mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years.
  • The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union.
  • "Health Canada was the first regulator to approve our COVID-19 vaccine fully. We are pleased they have taken this important step to expand this authorization to children aged 6 to11 years," said Stéphane Bancel, Chief Executive Officer of Moderna. 
  • Also Read: Alnylam Pharmaceuticals Files Patent Infringement Suits Against Pfizer And Moderna.
  • Moderna's vaccine was investigated in the ongoing Phase 2/3 KidCOVE study. 
  • Data submitted to Health Canada from over 4,000 children demonstrated that vaccination with a 50 μg mRNA-1273 was non-inferior in anti-SARS-CoV-2 neutralizing antibody responses compared to 18 to 25 years old from the Phase 3 COVE study. 
  • Price Action: MRNA shares are down 1.15% at $167.42 during the market session on the last check Thursday.
  • Photo by mufidpwt via Pixaby
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...